BRPI0610343B8 - composto derivado de morfinan substituído por 7-carbamoíla 6,7-insaturada, composição farmacêutica e uso do mesmo - Google Patents

composto derivado de morfinan substituído por 7-carbamoíla 6,7-insaturada, composição farmacêutica e uso do mesmo

Info

Publication number
BRPI0610343B8
BRPI0610343B8 BRPI0610343A BRPI0610343A BRPI0610343B8 BR PI0610343 B8 BRPI0610343 B8 BR PI0610343B8 BR PI0610343 A BRPI0610343 A BR PI0610343A BR PI0610343 A BRPI0610343 A BR PI0610343A BR PI0610343 B8 BRPI0610343 B8 BR PI0610343B8
Authority
BR
Brazil
Prior art keywords
optionally substituted
lower alkyl
morphinan
unsaturated
hydrogen
Prior art date
Application number
BRPI0610343A
Other languages
English (en)
Portuguese (pt)
Inventor
Inagaki Masanao
Haga Nobuhiro
Hara Shin-Ichiro
Hasegawa Tsuyoshi
Goto Yoshihisa
Tamura Yoshinori
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of BRPI0610343A2 publication Critical patent/BRPI0610343A2/pt
Publication of BRPI0610343B1 publication Critical patent/BRPI0610343B1/pt
Publication of BRPI0610343B8 publication Critical patent/BRPI0610343B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0610343A 2005-05-25 2006-05-25 composto derivado de morfinan substituído por 7-carbamoíla 6,7-insaturada, composição farmacêutica e uso do mesmo BRPI0610343B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2005-151864 2005-05-25
JP2005151864 2005-05-25
JP2006065762 2006-03-10
JP2006-065762 2006-03-10
PCT/JP2006/310231 WO2006126529A1 (ja) 2005-05-25 2006-05-23 ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
JPPCT/JP2006/310231 2006-05-23
PCT/JP2006/310454 WO2006126637A1 (ja) 2005-05-25 2006-05-25 ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体

Publications (3)

Publication Number Publication Date
BRPI0610343A2 BRPI0610343A2 (pt) 2010-06-15
BRPI0610343B1 BRPI0610343B1 (pt) 2020-03-10
BRPI0610343B8 true BRPI0610343B8 (pt) 2021-05-25

Family

ID=37451954

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610343A BRPI0610343B8 (pt) 2005-05-25 2006-05-25 composto derivado de morfinan substituído por 7-carbamoíla 6,7-insaturada, composição farmacêutica e uso do mesmo

Country Status (20)

Country Link
US (4) USRE46365E1 (enExample)
EP (1) EP1889848B8 (enExample)
JP (1) JP4323547B2 (enExample)
KR (1) KR100912782B1 (enExample)
CN (1) CN101228172B (enExample)
AU (1) AU2006250390B2 (enExample)
BE (1) BE2019C533I2 (enExample)
BR (1) BRPI0610343B8 (enExample)
CA (1) CA2609733C (enExample)
DK (1) DK1889848T3 (enExample)
ES (1) ES2525215T3 (enExample)
FR (1) FR19C1042I2 (enExample)
HU (1) HUS1900034I1 (enExample)
MX (1) MX2007014588A (enExample)
NL (1) NL300996I2 (enExample)
PL (1) PL1889848T3 (enExample)
PT (1) PT1889848E (enExample)
RU (1) RU2403255C2 (enExample)
TW (1) TWI311056B (enExample)
WO (2) WO2006126529A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
WO2009089494A2 (en) * 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions
JP5252391B2 (ja) * 2008-02-21 2013-07-31 学校法人北里研究所 オキサビシクロ［２．２．２］オクタンを有するモルヒナン誘導体およびその医薬用途
AU2009292631A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
CA2774021A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
WO2011142620A2 (en) * 2010-05-13 2011-11-17 Green Cross Corporation (+)-3-hydroxymorphinan-based polycycle derivatives as neuroprotectants
US9108975B2 (en) * 2010-11-12 2015-08-18 Shionogi & Co., Ltd. Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same
JP5818219B2 (ja) * 2012-05-14 2015-11-18 塩野義製薬株式会社 ６，７−不飽和−７−カルバモイルモルヒナン誘導体含有製剤
US11135217B2 (en) 2016-12-26 2021-10-05 Shionogi & Co., Ltd. Manufacturing process of formulation having improved content uniformity
EP3773573A4 (en) 2018-04-12 2022-04-06 Morphic Therapeutic, Inc. ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4) (BETA7)
KR102201609B1 (ko) 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
RS66976B1 (sr) 2019-10-16 2025-07-31 Morphic Therapeutic Inc Inhibiranje ljudskog integrina alfa4beta7
JP7582961B2 (ja) 2019-11-20 2024-11-13 塩野義製薬株式会社 ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有固形製剤
CN111905111B (zh) * 2020-09-16 2023-03-31 地奥集团成都药业股份有限公司 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法
IT202300009864A1 (it) * 2023-05-16 2024-11-16 Procos Spa Processo per la preparazione di naldemedina

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4275205A (en) 1980-05-05 1981-06-23 Miles Laboratories, Inc. 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols
US4347361A (en) 1980-12-10 1982-08-31 Sisa, Incorporated 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4443605A (en) 1982-07-30 1984-04-17 Miles Laboratories, Inc. 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans
US4440932A (en) 1982-09-09 1984-04-03 Miles Laboratories, Inc. 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
CA2143864C (en) 1993-07-23 2006-01-24 Hiroshi Nagase Morphinan derivatives and pharmaceutical use thereof
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
TR199801348T2 (xx) 1996-01-10 1998-10-21 Smithkline Beecham S.P.A. Heterosikl-kondanse morfinoid t�revleri(II).
WO2001002375A1 (en) 1999-07-01 2001-01-11 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
AU784541B2 (en) 1999-11-29 2006-04-27 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
CA2408106A1 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
AU2001259560B2 (en) * 2000-05-05 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
EP1353909B1 (en) * 2000-10-31 2005-04-06 Rensselaer Polytechnic Institute 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioidreceptor binding agents
WO2002042309A1 (en) * 2000-11-22 2002-05-30 Toray Industries, Inc. Indole derivatives and use thereof in medicines
PL368732A1 (en) * 2001-08-23 2005-04-04 Akzo Nobel N.V. C-14 oxidation of morphine derivatives
DE10161963A1 (de) 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
WO2004007503A1 (ja) * 2002-07-11 2004-01-22 Toray Industries, Inc. 悪心・嘔吐の治療または予防剤
EP1539767A4 (en) 2002-09-18 2006-07-19 Univ Missouri FOR THE DELTA OPIOID RECEPTOR SELECTIVE OPIATANALOGA
US20040157784A1 (en) 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
WO2005105093A2 (en) 2003-08-26 2005-11-10 Duke University METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION
US8481501B2 (en) 2004-05-28 2013-07-09 Human Biomolecular Research Institute Synthesis of metabolically stable analgesics, pain medications and other agents
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US7142420B2 (en) 2004-09-20 2006-11-28 Qualcomm, Incorporated Devices and methods for controlling relative movement between layers of an electronic device
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
US9108975B2 (en) 2010-11-12 2015-08-18 Shionogi & Co., Ltd. Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same

Also Published As

Publication number Publication date
PL1889848T3 (pl) 2015-04-30
JPWO2006126637A1 (ja) 2008-12-25
AU2006250390A1 (en) 2006-11-30
EP1889848B1 (en) 2014-10-15
US20120135978A1 (en) 2012-05-31
USRE46365E1 (en) 2017-04-11
US8084460B2 (en) 2011-12-27
CA2609733A1 (en) 2006-11-30
FR19C1042I1 (enExample) 2019-08-09
RU2007148412A (ru) 2009-06-27
JP4323547B2 (ja) 2009-09-02
US8536192B2 (en) 2013-09-17
RU2403255C2 (ru) 2010-11-10
CN101228172A (zh) 2008-07-23
BRPI0610343B1 (pt) 2020-03-10
NL300996I1 (nl) 2019-07-03
PT1889848E (pt) 2014-12-09
US20090203723A1 (en) 2009-08-13
WO2006126529A1 (ja) 2006-11-30
FR19C1042I2 (fr) 2020-06-19
DK1889848T3 (en) 2014-12-01
EP1889848A4 (en) 2011-08-10
USRE46375E1 (en) 2017-04-25
EP1889848B8 (en) 2014-12-17
BRPI0610343A2 (pt) 2010-06-15
CN101228172B (zh) 2013-04-03
EP1889848A1 (en) 2008-02-20
CA2609733C (en) 2011-07-19
BE2019C533I2 (enExample) 2025-12-10
HUS1900034I1 (hu) 2019-07-29
TWI311056B (en) 2009-06-21
KR100912782B1 (ko) 2009-08-18
WO2006126637A1 (ja) 2006-11-30
ES2525215T3 (es) 2014-12-19
AU2006250390B2 (en) 2010-07-08
MX2007014588A (es) 2008-01-24
TW200726470A (en) 2007-07-16
NL300996I2 (nl) 2019-07-30
KR20080014791A (ko) 2008-02-14

Similar Documents

Publication Publication Date Title
BRPI0610343B8 (pt) composto derivado de morfinan substituído por 7-carbamoíla 6,7-insaturada, composição farmacêutica e uso do mesmo
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
GT200400092A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
BRPI0814957B8 (pt) composto, agente farmacêutico, e, uso do composto
BRPI0517343A (pt) derivados de betulina, preparação destes e uso dos mesmos
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
DE602004022404D1 (de) 4-anilino-chinazolin-derivate als proliferationshemmende mittel
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
BRPI0413233A (pt) novos compostos
UY31736A (es) Derivados sustituidos de pirazol y su uso
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
WO2007103187A3 (en) 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
PT2280706E (pt) Composições compreendendo derivados de benzeno que activam lipase de lipoproteína
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
BR112014010566A2 (pt) compostos pesticidas
MX2009008756A (es) Compuesto macrociclico.
BR0310032A (pt) Derivados de benzoxazina como moduladores de 5-ht6 e usos dos mesmos
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
BR112012009861A2 (pt) composto, composição farmacêutica, e, uso do composto.
UY27980A1 (es) Indoles 2,7-sustituidos
MX2013007296A (es) Derivado novedoso de isoquinolina sustituido.
BR112012009311A2 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0821611A8 (pt) Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/05/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2776 DE 19-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.